Connor, Clark & Lunn Investment Management Ltd.

Position in LRMR — Larimar Therapeutics, Inc.

CIK 1596800 VANCOUVER, A1

Position in LRMR

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$310,891

+$230,615 QoQ

Shares Held

69,087

+227.9% QoQ

Ownership

0.067%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. LRMR ranks #87 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$310,891	69,087	+227.9%	Shares	Sole	2026-05-11
2025-12-31	$80,276	21,070	-10.4%	Shares	Sole	2026-02-10
2024-09-30	$154,062	23,521	-1.3%	Shares	Sole	2024-11-08
2024-06-30	$172,782	23,832	-59.0%	Shares	Sole	2024-08-09
2024-03-31	$441,100	58,116	+166.2%	Shares	Sole	2024-05-09
2023-09-30	$86,248	21,835	-54.6%	Shares	Sole	2023-11-13
2023-06-30	$150,471	48,074	+14.9%	Shares	Sole	2023-08-10
2023-03-31	$189,566	41,847	+11.6%	Shares	Sole	2023-05-10
2022-12-31	$154,813	37,485	+186.9%	Shares	Sole	2023-02-10
2022-09-30	$41,808	13,065	—	Shares	Sole	2022-11-10
No filing history on record for this holder in this stock.